FR24C1012I1 - Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés - Google Patents

Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés

Info

Publication number
FR24C1012I1
FR24C1012I1 FR24C1012C FR24C1012C FR24C1012I1 FR 24C1012 I1 FR24C1012 I1 FR 24C1012I1 FR 24C1012 C FR24C1012 C FR 24C1012C FR 24C1012 C FR24C1012 C FR 24C1012C FR 24C1012 I1 FR24C1012 I1 FR 24C1012I1
Authority
FR
France
Prior art keywords
glucosidase
acid alpha
improved carbon
carbon hydrates
highly powerful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1012C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of FR24C1012I1 publication Critical patent/FR24C1012I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR24C1012C 2014-09-30 2024-03-28 Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés Active FR24C1012I1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462057842P 2014-09-30 2014-09-30
US201462057847P 2014-09-30 2014-09-30
US201562112463P 2015-02-05 2015-02-05
US201562135345P 2015-03-19 2015-03-19
PCT/US2015/053252 WO2016054231A1 (en) 2014-09-30 2015-09-30 Highly potent acid alpha-glucosidase with enhanced carbohydrates

Publications (1)

Publication Number Publication Date
FR24C1012I1 true FR24C1012I1 (fr) 2024-05-24

Family

ID=55631441

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1012C Active FR24C1012I1 (fr) 2014-09-30 2024-03-28 Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés

Country Status (37)

Country Link
US (5) US10208299B2 (ru)
EP (2) EP3201320B1 (ru)
JP (3) JP6851964B2 (ru)
KR (3) KR20220146662A (ru)
CN (2) CN114540327A (ru)
AU (2) AU2015325028B2 (ru)
BR (1) BR112017005810A2 (ru)
CA (2) CA3228032A1 (ru)
CL (1) CL2017000722A1 (ru)
CO (1) CO2017002776A2 (ru)
CR (1) CR20170107A (ru)
DK (1) DK3201320T5 (ru)
DO (1) DOP2017000079A (ru)
EA (1) EA038986B1 (ru)
EC (1) ECSP17019103A (ru)
ES (1) ES2967620T3 (ru)
FI (2) FI3201320T3 (ru)
FR (1) FR24C1012I1 (ru)
HR (1) HRP20240041T1 (ru)
HU (2) HUE064629T2 (ru)
IL (4) IL307587A (ru)
LT (1) LT3201320T (ru)
MX (2) MX2017003989A (ru)
MY (1) MY186336A (ru)
NI (1) NI201700039A (ru)
NZ (1) NZ768484A (ru)
PE (1) PE20170906A1 (ru)
PH (1) PH12017500455A1 (ru)
PL (1) PL3201320T3 (ru)
PT (1) PT3201320T (ru)
RS (1) RS65066B1 (ru)
SG (2) SG11201702114TA (ru)
SI (1) SI3201320T1 (ru)
SV (1) SV2017005416A (ru)
TN (1) TN2017000082A1 (ru)
WO (1) WO2016054231A1 (ru)
ZA (2) ZA201701945B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados
DK3957320T5 (da) * 2015-12-30 2024-08-05 Amicus Therapeutics Inc Forstærket syre-alfa-glucosidase til behandling af pompes sygdom
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
KR102444612B1 (ko) 2016-03-30 2022-09-21 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
TW202411239A (zh) * 2016-03-30 2024-03-16 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
JP7193476B2 (ja) 2017-05-15 2022-12-20 アミカス セラピューティックス インコーポレイテッド 組換えヒト酸性アルファグリコシダーゼ
CA3149955A1 (en) 2019-09-06 2021-03-11 Kumar DHANASEKHARAN Method for capturing and purification of biologics
IL305103A (en) * 2021-02-11 2023-10-01 Amicus Therapeutics Inc Recombinant human acid alpha glucosidase and uses thereof
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
WO2023215865A1 (en) * 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Methods for treating pompe disease
WO2024119091A1 (en) 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients
WO2024119070A1 (en) 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Methods for treating late onset pompe disease in pediatric patients

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1030839B1 (en) 1997-11-10 2004-02-04 G.D. SEARLE & CO. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
US6545021B1 (en) 1999-02-12 2003-04-08 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK3108895T3 (en) 2000-07-18 2018-11-26 Univ Duke Treatment of glycogen storage disease type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
MXPA04003640A (es) 2001-10-16 2005-04-11 Rxkinetix Inc Formulaciones de proteina de alta concentracion y metodo de fabricacion.
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CA2556245A1 (en) * 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
ATE465250T1 (de) 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN101636200A (zh) * 2006-11-13 2010-01-27 齐斯特治疗公司 用于治疗庞贝氏症的方法
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2252288A1 (en) 2007-11-21 2010-11-24 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
PT3470077T (pt) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
JP2011512876A (ja) 2008-03-12 2011-04-28 アミカス セラピューティックス インコーポレイテッド 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視
JP2011517556A (ja) 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
EP2279210B1 (en) * 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) * 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CN105879047A (zh) * 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
US8466340B2 (en) * 2009-02-18 2013-06-18 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
JP5415170B2 (ja) 2009-07-21 2014-02-12 富士フイルム株式会社 複眼撮像装置
CA2775938C (en) 2009-09-29 2021-08-10 Oxyrane Uk Limited Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
EP2622088A2 (en) * 2010-09-29 2013-08-07 Oxyrane UK Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
US20140186326A1 (en) 2011-04-22 2014-07-03 William Canfield Modified acid alpha glucosidase with accelerated processing
CN108586621A (zh) * 2011-05-27 2018-09-28 阿米库斯治疗学公司 将靶向肽偶联于重组溶酶体酶上的方法
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013016249A2 (en) * 2011-07-22 2013-01-31 Insight Photonic Solutions, Inc. System and method of dynamic and adaptive creation of a wavelength-continuous and prescribed wavelength versus time sweep from a laser
JP6320931B2 (ja) 2011-12-22 2018-05-09 セントジーン アイピー ゲーエムベーハー リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ
KR20140135222A (ko) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
PT2844279T (pt) * 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe
CA2915127A1 (en) 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados

Also Published As

Publication number Publication date
CO2017002776A2 (es) 2017-08-10
RS65066B1 (sr) 2024-02-29
ECSP17019103A (es) 2017-06-30
AU2022203498A1 (en) 2022-06-09
HUS2400007I1 (hu) 2024-04-28
EA038986B1 (ru) 2021-11-18
KR20170063837A (ko) 2017-06-08
NZ768484A (en) 2024-05-31
US20210261935A1 (en) 2021-08-26
KR102306577B1 (ko) 2021-10-01
CR20170107A (es) 2017-09-01
EP3201320A1 (en) 2017-08-09
HUE064629T2 (hu) 2024-04-28
IL277529B (en) 2022-02-01
BR112017005810A2 (pt) 2018-02-27
ES2967620T3 (es) 2024-05-03
PE20170906A1 (es) 2017-07-12
SG11201702114TA (en) 2017-04-27
CN107075468A (zh) 2017-08-18
IL289383A (en) 2022-02-01
PL3201320T3 (pl) 2024-03-18
US10208299B2 (en) 2019-02-19
LT3201320T (lt) 2024-01-25
JP2021011489A (ja) 2021-02-04
PT3201320T (pt) 2024-01-12
JP7225176B2 (ja) 2023-02-20
IL307587A (en) 2023-12-01
JP2023078118A (ja) 2023-06-06
CN107075468B (zh) 2021-12-24
KR102455814B1 (ko) 2022-10-18
IL277529A (en) 2020-11-30
EP4273241A3 (en) 2024-01-24
JP6851964B2 (ja) 2021-03-31
SG10202003753PA (en) 2020-05-28
KR20220146662A (ko) 2022-11-01
FIC20240010I1 (fi) 2024-04-03
US11753632B2 (en) 2023-09-12
DOP2017000079A (es) 2017-05-31
AU2015325028B2 (en) 2022-02-24
US20170298335A1 (en) 2017-10-19
NZ729507A (en) 2021-10-29
EP3201320A4 (en) 2018-03-14
JP2017537604A (ja) 2017-12-21
MX2021014565A (es) 2022-01-11
EP3201320B1 (en) 2023-10-11
DK3201320T5 (da) 2024-10-14
DK3201320T3 (da) 2024-01-08
US20190276812A1 (en) 2019-09-12
SI3201320T1 (sl) 2024-02-29
IL289383B2 (en) 2024-03-01
EP4273241A2 (en) 2023-11-08
CA2961762C (en) 2024-03-05
ZA201901690B (en) 2022-06-29
MX2017003989A (es) 2017-07-07
CL2017000722A1 (es) 2017-12-15
TN2017000082A1 (en) 2018-07-04
NI201700039A (es) 2018-01-05
EA201790724A1 (ru) 2017-08-31
CA2961762A1 (en) 2016-04-07
CN114540327A (zh) 2022-05-27
AU2015325028A1 (en) 2017-03-16
WO2016054231A1 (en) 2016-04-07
CA3228032A1 (en) 2016-04-07
US20230203465A1 (en) 2023-06-29
MY186336A (en) 2021-07-13
IL289383B1 (en) 2023-11-01
IL251152A0 (en) 2017-04-30
US20220162578A1 (en) 2022-05-26
US10961522B2 (en) 2021-03-30
SV2017005416A (es) 2017-08-08
HRP20240041T1 (hr) 2024-03-29
PH12017500455A1 (en) 2017-07-31
IL251152B (en) 2021-06-30
FI3201320T3 (fi) 2024-01-08
ZA201701945B (en) 2019-06-26
KR20210118977A (ko) 2021-10-01
US11591583B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
FR24C1012I1 (fr) Alpha-glucosidase acide très puissante ayant des hydrates de carbone améliorés
MA41217A (fr) Polythérapies ayant des souches de listeria recombinées
SI3119918T1 (sl) Nizkostroškovno jeklo z izjemno visoko prevodnostjo
KR20180084862A (ko) 탄소 복합체
SI3094593T1 (sl) Mikro postrojenje za proizvodnjo ogljika
GB201405834D0 (en) Oncolytic virus
DK3200213T3 (da) Jævnstrømsafbryder
FR3016371B1 (fr) Levures modifiees pour utiliser le dioxyde de carbone
EP3194335A4 (en) Carbon composites
GB201403063D0 (en) Quantum technology
SG11201505201TA (en) Protein purification in the presence of nonionic organic polymers at elevated conductivity
DK3221269T3 (da) Forbedret ballasteret klaringsfremgangsmåde
GB2540285B (en) Carbon nanotube transistor having extended contacts
EP3190991A4 (en) High intensity ultrasonic tongue cleaner
GB201421830D0 (en) Carbon Nanotube
DK3099515T3 (da) Massivt dæk med trækkabel
CL2015001184S1 (es) Conector
PL3052650T3 (pl) Wykrywanie mykobakterii za pomocą bakteriofagów
ES1135607Y (es) Laringoscopio con pala fungible
ES1130981Y (es) Lampara electrica
FR3022212B1 (fr) Tricycle utilitaire ameliore
TH1601003812A (th) วิธีและออร์แกนิซึมที่มีประสิทธิภาพคาร์บอนฟลักซ์เพิ่มขึ้น
TH1601002158A (th) การดักจับคาร์บอนในการหมักที่ถูกทำให้ดีขึ้น
GB201419474D0 (en) Carbon nanotube
ES2654061T8 (es) Conector